High-Titer Recombinant Adenovirus 26 Vector GMP Manufacturing in HEK 293 Cells with a Stirred Single-Use Bioreactor for COVID-19 Vaccination Purposes

利用搅拌式一次性生物反应器在HEK 293细胞中生产高滴度重组腺病毒26载体GMP,用于COVID-19疫苗接种

阅读:1

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) pandemic has shown the importance of pursuing various vaccine manufacturing strategies. In the present study, the HEK 293 cells were infected with recombinant adenovirus serotype 26 (rAd26), and the effects of critical process parameters (CPPs) including viable cell density (VCD) at infection time (0.5 × 10(6), 0.8 × 10(6), 1.4 × 10(6), 1.8 × 10(6), and 2.5 × 10(6) cells/mL), the multiplicity of infection (MOI) = 3, 6, 9, 12, and 15, and two aeration strategies (high-speed agitation with a sparging system and low-speed agitation with an overlay system) were investigated experimentally. The results of small-scale experiments in 2 L shake flasks (SF 2L) demonstrated that the initial VCD and MOI could affect the cell proliferation and viability. The results at these experiments showed that VCD = 1.4 × 10(6) cells/mL and MOI = 9 yielded TCID(50) /mL = 10(8.9), at 72 h post-infection (hpi), while the virus titer at VCD = 0.5 × 10(6) and 0.8 × 10(6) cells/mL was lower compared to that of VCD = 1.4 × 10(6) cells/mL. Moreover, our findings showed that VCDs > 1.8 × 10(6) cells/m with MOI = 9 did not have a positive effect on TCID(50) /mL and MOI = 3 and 6 were less efficient, whereas MOI > 12 decreased the viability drastically. In the next step, the optimized CPPs in a small scale were exploited in a 200 L single-use bioreactor (SUB), with good manufacturing practice (GMP) conditions, at RPM = 25 with an overlay system, yielding high-titer rAd26 manufacturing, i.e., TCID(50)/mL = 10(8.9), at 72 hpi.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。